28 October 2020: Clinical Research
Need for Greater Attention to Joint Damage in Rhupus Patients: Results from an Ultrasound Study
Zhi-Xin Chen 123BCE* , Pei-Dan Yang 12CDE* , Min-Ying Liu 12BCE* , Ping-Fang Song 4EF , Qiang Xu 12AEFG*DOI: 10.12659/MSM.927104
Med Sci Monit 2020; 26:e927104
Table 1 Clinical characteristics of rhupus patients and SLE with arthropathy patients.
| Clinical manifestations | Rhupus | SLE with arthropathy | P value |
|---|---|---|---|
| Age, years, mean±S.D | 47.31±4.35 | 38.58±2.50 | 0.040* |
| Gender, male: female | 2: 8 | 7: 26 | 0.934 |
| Duration of disease, months, median(IQR) | 72 (4–192) | 12 (1–240) | 0.040* |
| Onset age, years, mean±S.D | 41.53±4.68 | 35.58±2.48 | 0.083 |
| Cutaneous involvement, n (%) | 1/10 (10.00%) | 13/33 (39.39%) | 0.082 |
| Raynaud Syndrome, n (%) | 1/10 (0.00%) | 13/33 (39.39%) | 0.082 |
| Renal involvement, n (%) | 1/10 (10.00%) | 12/33 (36.36%) | 0.112 |
| Serositis, n (%) | 1/10 (10.00%) | 5/33 (15.15%) | 0.680 |
| Neuropsychiatric involvement, n (%) | 0/6 (0.00%) | 2/13 (15.38%) | 0.310 |
| Cytopenia, n (%) | 8/10 (80.00%) | 28/33 (84.85%) | 0.716 |
| Lung involvement, n (%) | 6/10 (60.00%) | 12/33 (36.36%) | 0.184 |
| ILD, n (%) | 4/10 (40.00%) | 9/33 (27.27%) | 0.443 |
| PAH, n (%) | 4/9 (44.44%) | 4/28 (14.29%) | 0.056 |
| * P SLE – systemic lupus erythematosus; S.D – standard deviation; IQR – interquartile range; ILD – interstitial lung disease; PAH – pulmonary artery pressure. Categorical variables are expressed as number (percentage); continuous variables are expressed as mean±standard deviation (S.D) or median [interquartile range]. | |||